Castle Biosciences reported Q2 revenue of $103.5 million as core test volume rose 32% from a year earlier. The diagnostics company also raised its outlook, sign

Castle Biosciences reported Q2 revenue of $103.5 million as core test volume rose 32% from a year earlier. The diagnostics company also raised its outlook, signaling sustained demand for products including DecisionDx Melanoma and TissueCypher.